These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 8617299)
41. Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease. De Lazzari F; Ravagnan P; Tenderini M; Vicarioto MA; Galliani EA; Lorenzoni U; Popovic A; Floreani A Hepatogastroenterology; 2002; 49(43):231-4. PubMed ID: 11941962 [TBL] [Abstract][Full Text] [Related]
42. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nakao K; Nagake Y; Okamoto A; Ichikawa H; Yamamura M; Makino H Nephron; 2002 Jun; 91(2):215-21. PubMed ID: 12053056 [TBL] [Abstract][Full Text] [Related]
43. Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. Kusanovic JP; Romero R; Hassan SS; Gotsch F; Edwin S; Chaiworapongsa T; Erez O; Mittal P; Mazaki-Tovi S; Soto E; Than NG; Friel LA; Yoon BH; Espinoza J J Matern Fetal Neonatal Med; 2007 Dec; 20(12):867-78. PubMed ID: 17853188 [TBL] [Abstract][Full Text] [Related]
44. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy. Dle Beato T; Berghella AM; Pellegrini P; Domenico A; Casciani CU Cancer Biother Radiopharm; 1997 Oct; 12(5):297-304. PubMed ID: 10851480 [TBL] [Abstract][Full Text] [Related]
45. Role for CD30 antigen in human T helper 2-type responses. Romagnani S Ciba Found Symp; 1995; 195():55-62; discussion 62-7. PubMed ID: 8724830 [TBL] [Abstract][Full Text] [Related]
46. CD30(+) cutaneous lymphoproliferative disorders with pseudocarcinomatous hyperplasia are associated with a T-helper-17 cytokine profile and infiltrating granulocytes. Guitart J; Martinez-Escala ME; Deonizio JM; Gerami P; Kadin ME J Am Acad Dermatol; 2015 Mar; 72(3):508-15. PubMed ID: 25582534 [TBL] [Abstract][Full Text] [Related]
47. Soluble CD30 serum levels before and after treatment with alpha-interferon in patients with chronic hepatitis C. Di Cesare E; Spadaro A; Ajello A; Ferraù O; Alessi N; Luigiano C; Melluso R; Freni MA Clin Chem Lab Med; 2005; 43(8):823-6. PubMed ID: 16201891 [TBL] [Abstract][Full Text] [Related]
48. The Omenn's syndrome: histological, immunohistochemical and ultrastructural evidence for a partial T cell deficiency evolving in an abnormal proliferation of T lymphocytes and S-100 +/T-6 + Langerhans-like cells. Ruco LP; Stoppacciaro A; Pezzella F; Mirolo M; Uccini S; Barsotti P; Cassano AM; Boner AL; Businco L; Di Fazio A Virchows Arch A Pathol Anat Histopathol; 1985; 407(1):69-82. PubMed ID: 3925627 [TBL] [Abstract][Full Text] [Related]
49. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD). Giacomelli R; Passacantando A; Parzanese I; Vernia P; Klidara N; Cucinelli F; Lattanzio R; Santori E; Cipriani P; Caprilli R; Tonietti G Clin Exp Immunol; 1998 Mar; 111(3):532-5. PubMed ID: 9528894 [TBL] [Abstract][Full Text] [Related]
50. Th1 and Th2 in human diseases. Romagnani S Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 1):225-35. PubMed ID: 8811042 [TBL] [Abstract][Full Text] [Related]
51. An update on human Th1 and Th2 cells. Romagnani S; Parronchi P; D'Elios MM; Romagnani P; Annunziato F; Piccinni MP; Manetti R; Sampognaro S; Mavilia C; De Carli M; Maggi E; Del Prete GF Int Arch Allergy Immunol; 1997; 113(1-3):153-6. PubMed ID: 9130508 [TBL] [Abstract][Full Text] [Related]
52. T-helper 2 involvement in the pathogenesis of bullous pemphigoid: role of soluble CD30 (sCD30). De Pitá O; Frezzolini A; Cianchini G; Ruffelli M; Teofoli P; Puddu P Arch Dermatol Res; 1997 Nov; 289(12):667-70. PubMed ID: 9452886 [TBL] [Abstract][Full Text] [Related]
53. Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1/Th2 balance? Hoshimoto K; Ohta N; Ohkura T; Inaba N Gynecol Obstet Invest; 2000; 50(4):260-3. PubMed ID: 11093050 [TBL] [Abstract][Full Text] [Related]
54. Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients. Contasta I; Totaro R; Berghella AM; Pellegrini P; Del Beato T; Carolei A; Adorno D Int J Immunopathol Pharmacol; 2010; 23(1):213-26. PubMed ID: 20378007 [TBL] [Abstract][Full Text] [Related]
55. CD26 and CD30 expression on the surface of lymphocyte during normal pregnancy. Hoshimoto K; Hayashi M; Ohkura T Gynecol Obstet Invest; 2001; 52(1):9-12. PubMed ID: 11549856 [TBL] [Abstract][Full Text] [Related]
56. T-Cell Surface Antigens and sCD30 as Biomarkers of the Risk of Rejection in Solid Organ Transplantation. Wieland E; Shipkova M Ther Drug Monit; 2016 Apr; 38 Suppl 1():S29-35. PubMed ID: 26495982 [TBL] [Abstract][Full Text] [Related]
57. Is CD30 (Ki-1) immunostaining in cutaneous eruptions useful as a marker of Th1 to Th2 cytokine switching and/or as a marker of advanced HIV-1 disease? Smith KJ; Barrett TL; Neafie R; Tomaszewski MM; Yeager J; Nelson A; Wagner KF; Skelton HG Br J Dermatol; 1998 May; 138(5):774-9. PubMed ID: 9666821 [TBL] [Abstract][Full Text] [Related]
58. Comparative study of CD26 as a Th1-like and CD30 as a potential Th2-like operational marker in leprosy. Seitzer U; Scheel-Toellner D; Hahn M; Heinemann G; Mattern T; Flad HD; Gerdes J Adv Exp Med Biol; 1997; 421():217-21. PubMed ID: 9330700 [TBL] [Abstract][Full Text] [Related]
59. CD30L up-regulates CD30 and IL-4 expression by T cells. Rossi FM; Degan M; Mazzocut-Zecchin L; Di Francia R; Aldinucci D; Pinto A; Gattei V FEBS Lett; 2001 Nov; 508(3):418-22. PubMed ID: 11728464 [TBL] [Abstract][Full Text] [Related]
60. [Neonatal erythrodermia - early manifestation of Omenn's syndrome]. Wozniakowska-Gesicka T; Wisniewska-Ligier M; Borowska-Rybus B Med Wieku Rozwoj; 2002; 6(1):23-9. PubMed ID: 12177510 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]